You're reading a free article with opinions that may differ from The Motley Fool's Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Is Hims & Hers in trouble since the FDA put a time clock on some GLP-1s, or is the future still bright?
Hims & Hers (HIMS 2.86%) stock has been on a roller coaster about the availability of GLP-1s to its customers. However, the focus on one treatment may miss the company's strategy. In this video, Travis Hoium shows why Hims & Hers will be fine with or without GLP-1s.
*Stock prices used were end-of-day prices of Oct. 7, 2024. The video was published on Oct. 8, 2024.
Travis Hoium has positions in Hims & Hers Health. The Motley Fool recommends CVS Health. The Motley Fool has a disclosure policy. Travis Hoium is an affiliate of The Motley Fool and may be compensated for promoting its services. If you choose to subscribe through their link they will earn some extra money that supports their channel. Their opinions remain their own and are unaffected by The Motley Fool.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
